Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Cell free fetal DNA (cfDNA) screening is a form of noninvasive prenatal testing (NIPT) used to determine the risk that a fetus will be born with certain genetic abnormalities.
Status: Decision completed
There is uncertainty about the appropriateness of cfDNA screening for some populations, including those at low risk for common fetal genetic abnormalities. This topic was selected for a health technology assessment because of medium concerns for the safety and efficacy of cfDNA screening in the general population and high concern for cost.
Type | Materials |
---|---|
Assessment (2019) |